GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (NYSE:RMD) » Definitions » Cyclically Adjusted Revenue per Share

ResMed (ResMed) Cyclically Adjusted Revenue per Share : $21.99 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is ResMed Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ResMed's adjusted revenue per share for the three months ended in Dec. 2023 was $7.881. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $21.99 for the trailing ten years ended in Dec. 2023.

During the past 12 months, ResMed's average Cyclically Adjusted Revenue Growth Rate was 11.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of ResMed was 26.90% per year. The lowest was 11.40% per year. And the median was 15.70% per year.

As of today (2024-04-27), ResMed's current stock price is $218.06. ResMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $21.99. ResMed's Cyclically Adjusted PS Ratio of today is 9.92.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ResMed was 18.37. The lowest was 6.12. And the median was 8.58.


ResMed Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for ResMed's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed Cyclically Adjusted Revenue per Share Chart

ResMed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.78 14.06 16.10 18.91 21.02

ResMed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.65 20.41 21.02 21.63 21.99

Competitive Comparison of ResMed's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, ResMed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ResMed's Cyclically Adjusted PS Ratio falls into.



ResMed Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ResMed's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=7.881/129.4194*129.4194
=7.881

Current CPI (Dec. 2023) = 129.4194.

ResMed Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 2.774 99.695 3.601
201406 2.900 100.560 3.732
201409 2.666 100.428 3.436
201412 2.974 99.070 3.885
201503 2.958 99.621 3.843
201506 3.170 100.684 4.075
201509 2.893 100.392 3.730
201512 3.214 99.792 4.168
201603 3.214 100.470 4.140
201606 3.661 101.688 4.659
201609 3.276 101.861 4.162
201612 3.733 101.863 4.743
201703 3.603 102.862 4.533
201706 3.900 103.349 4.884
201709 3.650 104.136 4.536
201712 4.180 104.011 5.201
201803 4.109 105.290 5.051
201806 4.323 106.317 5.262
201809 4.084 106.507 4.963
201812 4.511 105.998 5.508
201903 4.588 107.251 5.536
201906 4.865 108.070 5.826
201909 4.694 108.329 5.608
201912 5.057 108.420 6.036
202003 5.282 108.902 6.277
202006 5.271 108.767 6.272
202009 5.147 109.815 6.066
202012 5.464 109.897 6.435
202103 5.283 111.754 6.118
202106 5.975 114.631 6.746
202109 6.156 115.734 6.884
202112 6.086 117.630 6.696
202203 5.882 121.301 6.276
202206 6.220 125.017 6.439
202209 6.459 125.227 6.675
202212 7.013 125.222 7.248
202303 7.578 127.348 7.701
202306 7.601 128.729 7.642
202309 7.474 129.860 7.449
202312 7.881 129.419 7.881

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


ResMed  (NYSE:RMD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ResMed's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=218.06/21.99
=9.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ResMed was 18.37. The lowest was 6.12. And the median was 8.58.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ResMed Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of ResMed's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ResMed (ResMed) Business Description

Industry
Address
9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Executives
Brett Sandercock officer: Chief Financial Officer 17 GUINEVIERE COURT, CASTLE HILL, NEW SOUTH WALES C3 2154
Michael J. Farrell officer: Chief Executive Officer C/O REMED INC, 9001 SPECTRUM CTR. BLVD., SAN DIEGO, CA 92123
Michael J Rider officer: Global General Counsel 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Robert Andrew Douglas officer: President and COO 21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106
Kaushik Ghoshal officer: President, SaaS Business 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
David Pendarvis officer: Chief Administration Officer REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Karen Drexler director C/O DIADEXUS, INC., 343 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Justin Leong officer: President, Asia and LATAM C/O RESMED INC, 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Desney Tan director 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
John Hernandez director 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Lucile Blaise officer: President, Sleep & RC Business RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
James Hollingshead officer: President, Sleep Business C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Carol Burt director C/O WELLCARE HEALTH PLANS, INC., 8725 HENDERSON ROAD, TAMPA FL 33634
Resmed Inc director 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123

ResMed (ResMed) Headlines

From GuruFocus

Q2 2023 Resmed Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2022 Resmed Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Resmed Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2023 Resmed Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Resmed Inc at Macquarie Australia Conference Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Resmed Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Resmed Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024